Clinical calculator summary
Renal Cell Carcinoma (RCC) Prognosis Panel
Clinical calculator summary
Renal Cell Carcinoma (RCC) Prognosis Panel
This panel displays two distinct metastatic RCC prognostic models using shared source-locked component engines.
Evidence-based context for fast calculator use
- Purpose:
- Side-by-side IMDC (Heng) and historical MSKCC (Motzer 2002) prognostic classifications for metastatic RCC.
- Population:
- patients whose clinical question requires the component models displayed in the combined panel
- Factors:
- KPS < 80%?, Diagnosis to first-line systemic treatment < 1 year?, Hemoglobin < institutional or sex-specific LLN?, Corrected calcium > institutional ULN?, Absolute neutrophil count > institutional ULN?, Platelet count > institutional ULN?, Corrected calcium > 10 mg/dL?, LDH > 1.5 x institutional assay ULN?
- Reference:
- Heng DYC, et al. J Clin Oncol. 2009;27:5794-5799. Motzer RJ, et al. J Clin Oncol. 2002;20:289-296.
Pin your most used calculators here by clicking the star in the dropdown.
Renal Cell Carcinoma (RCC) Prognosis Panel
Clinical Context & Background
This panel displays two distinct metastatic RCC prognostic models using shared source-locked component engines. IMDC uses corrected calcium above the institutional ULN. MSKCC 2002 instead uses corrected calcium above the fixed 10 mg/dL cutoff, so the panel asks separate calcium questions.
IMDC and MSKCC are calculated independently and no combined score is created. Both component engines and the panel synthesis are implementation-verified. Historical group outcomes are not individualized predictions or treatment directives.
Changing from the former shared ca_high field to imdc_ca_high plus mskcc_ca_high is an unavoidable saved-form schema change required to reproduce both source models correctly. Existing calculator routes and calculator IDs remain unchanged.
Formula Logic
IMDC and MSKCC are calculated separately with model-specific calcium predicates; no combined clinical score is created.Reference Data
| System | Risk Group | Score | Historical Median OS |
|---|---|---|---|
| IMDC (Heng) | Favorable | 0 factors | 43.2 months |
| IMDC (Heng) | Intermediate | 1-2 factors | 22.5 months |
| IMDC (Heng) | Poor | 3-6 factors | 7.8 months |
| --- | --- | --- | --- |
| MSKCC (Motzer 2002) | Favorable | 0 factors | 30 months |
| MSKCC (Motzer 2002) | Intermediate | 1-2 factors | 14 months |
| MSKCC (Motzer 2002) | Poor | 3-5 factors | 5 months |
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
When To Use
- Use Renal Cell Carcinoma (RCC) Prognosis Panel when side-by-side IMDC (Heng) and historical MSKCC (Motzer 2002) prognostic classifications for metastatic RCC.
- Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.
How To Interpret
- Interpret the displayed result using the calculator-specific formula and reference table, spanning IMDC (Heng) through MSKCC (Motzer 2002).
- A boundary result should prompt input verification and clinical review rather than false precision.
What To Do Next
- Review every component result separately; if models disagree, verify inputs and follow the more cautious disease-specific pathway rather than averaging scores.
- Document the inputs, result, timing, and clinical context so the assessment can be reproduced.
Limitations
- A panel improves comparison but does not make component models interchangeable or create a new validated composite score.
- The result supports clinician judgment and does not independently determine treatment.
Validated Population
patients whose clinical question requires the component models displayed in the combined panel
How to apply this result
For a representative case, verify KPS < 80%?, Diagnosis to first-line systemic treatment < 1 year?, Hemoglobin < institutional or sex-specific LLN?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.
Calculation verification history
Verified
Calculation verification history
Verified: Production browser revalidation
- Three source-backed cases passed through all eight visible production controls at both-model scores 0/0, 1/1, and maximum 6/5.
- IMDC and MSKCC retained independent scores, categories, model-specific calcium predicates, historical outcomes, and calculation traces without a synthetic combined score.
- No unexpected N/A, stale control, literal undefined value, or browser-console error was observed.
Case-level evidence is retained in validation/browser-revalidation/panel-renal-risk-2026-08-03.json.
: Production browser validation
- Ten source-backed cases were exercised on the public production route through visible browser controls; 10/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
- Overall browser status: failed-console. medium: Production emitted minified React error #418 during route loads/reloads used by this run.
- Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.
Case-level production evidence is retained in validation/browser-production/panel-renal-risk.json.
: Exact input guidance for skipped and invalid components
- Skipped and partially completed IMDC and MSKCC results now use "Please review" and name the exact visible shared and component-specific entries in parentheses.
- No factor definition, threshold, projection, historical outcome, or component-isolation behavior changed.
All 974 existing panel assertions pass; current report remains applicable.
: Input-quality and partial-completion verification
- Added exact required and component-usage metadata for all eight fields; the IMDC-only and MSKCC-only groups are visibly optional at panel level.
- An entirely blank model-specific group now reports Skipped / Missing Input, while a partially completed or malformed group remains Invalid Input; valid siblings are preserved.
- 974/974 panel assertions passed, including ten new partial-completion, missing-versus-malformed, and metadata cases.
: Full validation test
- Verified 256 exhaustive eight-input combinations, 164 malformed envelopes, 224 MSKCC-preservation disturbances, and 320 IMDC-preservation disturbances; 964/964 panel-synthesis checks passed.
- Verified separate child snapshots, traces, matched rows, copy/save serialization, reset behavior, independent validity, and no combined clinical score.
: MSKCC component revalidated
- Connected the MSKCC child to the verified 2002 shared engine, separated the fixed 10 mg/dL MSKCC calcium cutoff from IMDC calcium above institutional ULN, and verified component parity and isolation.
- The complete panel remains in review until synthesis, browser, copy/save, reset, history, and its own report are independently validated.
: IMDC component revalidated
- Connected the IMDC child to the strict shared six-factor engine and verified 128 projections with LDH off and on.
- The complete panel remains in review until standalone MSKCC and panel synthesis verification are finished.
Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.
Related Tools
Frequently Asked Questions
When should Renal Cell Carcinoma (RCC) Prognosis Panel be used?
Use it for patients whose clinical question requires the component models displayed in the combined panel when all required inputs and the intended clinical setting are confirmed.
Can Renal Cell Carcinoma (RCC) Prognosis Panel determine treatment by itself?
No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.
Evidence-based oncology decision support. Verify with clinical guidelines.